Related Experiment Videos
Suppressive therapy with levothyroxine for solitary thyroid nodules
J L Reverter1, A Lucas, I Salinas
1Endocrinology Section, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Clinical Endocrinology
|January 1, 1992
Summary
Levothyroxine treatment did not reduce benign thyroid nodule size in a randomized study. Suppressive doses of levothyroxine were ineffective for managing solitary thyroid nodules.
Area of Science:
- Endocrinology
- Thyroidology
- Clinical Research
Background:
- Benign thyroid nodules are common, and their management often involves monitoring or intervention.
- Levothyroxine therapy is sometimes used to suppress thyroid-stimulating hormone (TSH) in patients with thyroid nodules, aiming to prevent growth.
Purpose of the Study:
- To evaluate the efficacy of TSH-suppressive dose levothyroxine therapy in reducing the size of benign thyroid nodules.
Main Methods:
- Prospective randomized study involving 40 euthyroid women with solitary, benign thyroid nodules.
- Group A received levothyroxine adjusted for TSH suppression; Group B did not.
- Clinical, hormonal, and ultrasound assessments were conducted every 3-6 months over a mean follow-up of 10.6 months.
Main Results:
- No significant difference in thyroid nodule diameter or volume was observed between the levothyroxine group and the control group.
- The mean levothyroxine dose required for TSH suppression was 2.82 +/- 0.6 mcg/kg/day.
- The number of nodules showing significant volume reduction was similar in both groups.
Conclusions:
- TSH-suppressive levothyroxine therapy is not effective in reducing the size of solitary benign thyroid nodules.
- Further research may be needed to explore alternative therapeutic strategies for benign thyroid nodules.